Clinical trial
Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality…
NCT00254748 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00254748 |
|---|---|
| Title | Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients |
| Official title | The Effect of Quetiapine on Psychotic-Like Symptoms in Borderline Personality Disordered Patients: A Randomised Placebo-Controlled Trial |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Borderline Personality Disorder |
| Intervention type | Drug |
| Interventions | Quetiapine fumarate, Placebo |
| Enrollment | 40 |
| Start date | Jun 1, 2004 |
| Completion | Jun 1, 2007 |
| First posted | Nov 17, 2005 |
| Last update posted | Jun 11, 2009 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: